Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Partnering With Lentigen to Develop New Gene Expression Products

NEW YORK (GenomeWeb News) – Invitrogen announced today that it will work with Maryland-based biotechnology company Lentigen to develop and market products and services for gene over-expression based on Lentigen’s lentiviral gene delivery technology and Invitrogen’s human gene collections and cloning and gene synthesis technologies.
Invitrogen said that it will provide Lentigen with access to its human and mouse gene libraries, which will be used in conjunction with lentiviral gene delivery systems to create new gene expression systems for mammalian cells.
Any products or services developed within the partnership will be commercialized exclusively by Invitrogen. Further terms of the alliance were not disclosed.
“Researchers will be able to easily obtain ready-to-use lentiviral particles carrying either customer-designed genetic elements or predetermined and validated gene sets from Invitrogen’s Ultimate ORF collection,” Invitrogen Vice President of Cloning and Protein Expression Nathan Wood said in a statement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.